-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For metastatic non-small cell lung cancer ( NSCLC ) with negative EGFR and ALK mutations , single-agent immunotherapy or combined chemotherapy is currently recommended as the first-line treatment
For metastatic non-small cell lung cancer ( NSCLC ) with negative EGFR and ALK mutations , single-agent immunotherapy or combined chemotherapy is currently recommended as the first-line treatment
Study inclusion criteria: NSCLC patients aged ≥18 years, stage III-IV, received first-line immune monotherapy or immune-combined chemotherapy
Study inclusion criteria: NSCLC patients aged ≥18 years, stage III-IV, received first-line immune monotherapy or immune-combined chemotherapy
Research Overview
Of the 4271 patients who received IO combined chemotherapy, 814 (19%) were squamous cell carcinoma and 3457 (81%) were non-squamous cell carcinoma
Of the 4271 patients who received IO combined chemotherapy, 814 (19%) were squamous cell carcinoma and 3457 (81%) were non-squamous cell carcinoma
Evaluation of the efficacy of IO combined with chemotherapy
There were 3041 patients receiving single-agent immunotherapy, of which 875 (29%) were squamous cell carcinoma and 2,166 (71%) were non-squamous cell carcinoma
There were 3041 patients receiving single-agent immunotherapy, of which 875 (29%) were squamous cell carcinoma and 2,166 (71%) were non-squamous carcinoma
Evaluation of the efficacy of IO monotherapy
In summary, real-world studies have evaluated that the survival of patients with advanced non-small cell lung cancer (NSCLC) treated by immunotherapy is lower than that in clinical studies, indicating that further improvements in treatment are needed
In summary, real-world studies have evaluated that the survival of patients with advanced non-small cell lung cancer (NSCLC) treated by immunotherapy is lower than that in clinical studies, indicating that further improvements in treatment are needed
Original source:
Waterhouse D, Lam J, Betts KA, et al.
Waterhouse D, Lam J, Betts KA, et al.
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Lung Cancer.
2021 Jun;156:41-49.
doi: 10.
1016/j .
lungcan.
2021.
04.
007.
Epub 2021 Apr 14.
PMID: 33894493.
Leave a message here